72P Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Tebe is a bispecific fusion protein that binds gp100 presented by HLA-A*02:01 on melanoma cells and engages CD3 T-cells. While tebe has significantly improved overall survival in HLA-A*02:01+ mUM pts, clinical benefit after disease progression is limited. Here, we examine the efficacy and safety of adding CLT to tebe upon radiological progression with tebe alone.
Authors
- Inderjit Mehmi (ORCID: https://orcid.org/0000-0002-2253-2206)
- R. Sullivan
- Kamaneh Montazeri
- M. Orloff
- Omid Hamid (ORCID: https://orcid.org/0000-0002-8238-4655)
- Michael S. Caplan (ORCID: https://orcid.org/0000-0003-3498-3503)
- Antoine Desîlets (ORCID: https://orcid.org/0000-0002-9382-7597)
- Rino S. Seedor (ORCID: https://orcid.org/0000-0002-8494-3289)
- Benjamin Izar (ORCID: https://orcid.org/0000-0003-2379-6702)
- T. Sato
- R.D. Carvajal
- Seema A. Khan (ORCID: https://orcid.org/0000-0002-6307-2023)
- Mariam El-Ashmawy (ORCID: https://orcid.org/0000-0002-2335-4827)
- A.N. Shoushtari
- T. Lim
Institutions
- Northwell Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- Thomas Jefferson University (US)
- Massachusetts General Hospital (US)
- Angeles Clinic and Research Institute (US)
- Sidney Kimmel Cancer Center (US)
- New York Oncology Hematology (US)
- Center for Cancer Research (US)
Publication Details
- Journal
- Immuno-Oncology Technology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1016/j.iotech.2024.100815
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00